The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia

Clinical trials of heat shock protein 90 (Hsp90) inhibitors have been limited by high toxicity. We previously showed that the Hsp90 inhibitor, SNX-7081, synergizes with and restores sensitivity to fludarabine nucleoside (2-FaraA) in human chronic lymphocytic leukemia (CLL) cells with lesions in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufman, Kimberley L., Jenkins, Yiping, Alomari, Munther, Mirzaei, Mehdi, Best, O. Giles, Pascovici, Dana, Mactier, Swetlana, Mulligan, Stephen P., Haynes, Paul A., Christopherson, Richard I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747384/
https://www.ncbi.nlm.nih.gov/pubmed/26556860

Ejemplares similares

Ejemplares similares